[MAYBANK] QoQ TTM Result on 31-Mar-2011 [#1]

Announcement Date
12-May-2011
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2011
Quarter
31-Mar-2011 [#1]
Profit Trend
QoQ- 2.74%
YoY- 135.43%
View:
Show?
TTM Result
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
Revenue 23,660,845 22,112,066 21,039,643 20,055,958 19,514,330 18,997,029 18,560,232 17.51%
PBT 6,875,194 6,706,607 6,270,467 5,901,032 5,780,604 5,618,538 5,370,408 17.84%
Tax -1,753,611 -1,774,299 -1,650,709 -1,559,463 -1,562,013 -1,503,201 -1,401,958 16.04%
NP 5,121,583 4,932,308 4,619,758 4,341,569 4,218,591 4,115,337 3,968,450 18.48%
-
NP to SH 4,883,968 4,750,211 4,450,278 4,208,436 4,096,224 3,964,478 3,818,167 17.78%
-
Tax Rate 25.51% 26.46% 26.33% 26.43% 27.02% 26.75% 26.11% -
Total Cost 18,539,262 17,179,758 16,419,885 15,714,389 15,295,739 14,881,692 14,591,782 17.25%
-
Net Worth 32,966,670 29,916,045 31,250,468 29,884,116 28,277,939 28,308,160 27,881,071 11.78%
Dividend
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
Div 5,087,797 4,381,228 4,381,228 5,118,987 5,118,987 3,893,113 3,893,113 19.47%
Div Payout % 104.17% 92.23% 98.45% 121.64% 124.97% 98.20% 101.96% -
Equity
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
Net Worth 32,966,670 29,916,045 31,250,468 29,884,116 28,277,939 28,308,160 27,881,071 11.78%
NOSH 7,530,075 7,479,011 7,428,030 7,324,358 7,158,066 7,075,801 7,078,929 4.19%
Ratio Analysis
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
NP Margin 21.65% 22.31% 21.96% 21.65% 21.62% 21.66% 21.38% -
ROE 14.81% 15.88% 14.24% 14.08% 14.49% 14.00% 13.69% -
Per Share
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
RPS 314.22 295.65 283.25 273.83 272.62 268.48 262.19 12.78%
EPS 64.86 63.51 59.91 57.46 57.23 56.03 53.94 13.03%
DPS 67.57 58.58 58.98 69.89 72.00 55.00 55.00 14.66%
NAPS 4.378 4.00 4.2071 4.0801 3.9505 4.0007 3.9386 7.28%
Adjusted Per Share Value based on latest NOSH - 7,324,358
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
RPS 196.08 183.24 174.36 166.21 161.72 157.43 153.81 17.51%
EPS 40.47 39.37 36.88 34.88 33.95 32.85 31.64 17.77%
DPS 42.16 36.31 36.31 42.42 42.42 32.26 32.26 19.47%
NAPS 2.732 2.4792 2.5898 2.4765 2.3434 2.3459 2.3105 11.78%
Price Multiplier on Financial Quarter End Date
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
Date 30/12/11 30/09/11 30/06/11 31/03/11 30/12/10 30/09/10 30/06/10 -
Price 8.58 8.00 8.94 8.96 8.50 8.80 7.56 -
P/RPS 2.73 2.71 3.16 3.27 3.12 3.28 2.88 -3.49%
P/EPS 13.23 12.60 14.92 15.59 14.85 15.71 14.02 -3.78%
EY 7.56 7.94 6.70 6.41 6.73 6.37 7.13 3.97%
DY 7.87 7.32 6.60 7.80 8.47 6.25 7.28 5.31%
P/NAPS 1.96 2.00 2.12 2.20 2.15 2.20 1.92 1.38%
Price Multiplier on Announcement Date
31/12/11 30/09/11 30/06/11 31/03/11 31/12/10 30/09/10 30/06/10 CAGR
Date 23/02/12 14/11/11 22/08/11 12/05/11 21/02/11 12/11/10 20/08/10 -
Price 8.70 8.25 8.64 8.74 8.86 9.20 8.13 -
P/RPS 2.77 2.79 3.05 3.19 3.25 3.43 3.10 -7.21%
P/EPS 13.41 12.99 14.42 15.21 15.48 16.42 15.07 -7.46%
EY 7.46 7.70 6.93 6.57 6.46 6.09 6.63 8.15%
DY 7.77 7.10 6.83 8.00 8.13 5.98 6.77 9.59%
P/NAPS 1.99 2.06 2.05 2.14 2.24 2.30 2.06 -2.27%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment